{
  "id": 1769622344984,
  "seqId": 170,
  "title": "Ocular Neuropathic Pain & Conjunctival Lesions: Clinical Compendium",
  "summary": "An exhaustive clinical guide detailing the pathophysiology and NICE-based treatment of corneal neuropathic pain, alongside the diagnosis, management, and malignant potential of pigmented and non-pigmented conjunctival lesions.",
  "date": "2026-01-28T17:45:44.984Z",
  "data": {
    "title": "Ocular Neuropathic Pain & Conjunctival Lesions: Clinical Compendium",
    "summary": "An exhaustive clinical guide detailing the pathophysiology and NICE-based treatment of corneal neuropathic pain, alongside the diagnosis, management, and malignant potential of pigmented and non-pigmented conjunctival lesions.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='40' stroke='#1565C0' stroke-width='2' fill='none'/><path d='M30 50 Q50 20 70 50 Q50 80 30 50' fill='#BBDEFB'/><circle cx='50' cy='50' r='12' fill='#1565C0'/><path d='M50 38 L50 42 M50 58 L50 62 M38 50 L42 50 M58 50 L62 50' stroke='#F44336' stroke-width='1'/><path d='M75 30 L85 20 M78 35 L88 25' stroke='#FFC107' stroke-width='2' stroke-linecap='round'/></svg>",
    "sections": [
      {
        "title": "Ocular Neuropathic Pain: Pathophysiology",
        "icon": "psychology",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "center": "Ocular Neuropathic Pain",
          "branches": [
            "Pain = response to tissue injury + subsequent inflammatory response",
            "Heightened sensitivity in inflamed & contiguous non-inflamed areas",
            "Plasticity of nociceptors and central nociceptive pathways (Central Sensitization)",
            "Maladaptive plasticity from Chronic Inflammation or resolution of persistent inflammation (e.g., DED)",
            "‘Pain without stain’ (Rosenthal P et al. 2009)",
            "Peripheral and central amplification",
            "Neuroimmune interactions (Peripheral & Central Nervous Systems)"
          ]
        }
      },
      {
        "title": "Neural Anatomical Changes in the Ocular Surface",
        "icon": "account_tree",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Aberrant regeneration",
          "Collateral axon growth",
          "Branching",
          "Tortuosity",
          "Nerve loss",
          "Neuroma formation",
          "Beading"
        ]
      },
      {
        "title": "Treatment Strategy: Corneal Neuropathic Pain",
        "icon": "medical_services",
        "type": "process",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Step 1: Major focus for DEWS II - Treat as ocular surface disease",
          "Step 2: Follow NICE guidance (NICE CG173) for neuropathic pain management"
        ]
      },
      {
        "title": "Box 6.1: First Line Treatment",
        "icon": "looks_one",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "Oral Gabapentin",
          "Start 100mg 1×/d; increase 100mg increments every 2–3 days to improve compliance.",
          "Aim for a dose of 300mg 2×/d or 300mg 3×/d on Day 3.",
          "Dose may be increased according to response in steps of 100mg every 2–3d up to maximum of 3.6g/d."
        ]
      },
      {
        "title": "Box 6.1: Second Line Treatment",
        "icon": "looks_two",
        "type": "table",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": {
          "headers": [
            "Medication",
            "Dosing & Administration"
          ],
          "rows": [
            [
              "Oral Amitriptyline Hydrochloride",
              "Addition to low-dose gabapentin. Initially 10mg nocte, gradually increase if necessary to 75mg/d; higher doses under pain specialist supervision."
            ],
            [
              "Oral Pregabalin",
              "Replacement for gabapentin if ineffective or adverse effects. Start 25mg 2×/d; increase at 25mg twice daily increments up to 150mg 2×/d."
            ]
          ]
        }
      },
      {
        "title": "Box 6.1: Third Line Treatment & Rescue",
        "icon": "looks_3",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "Duloxetine: 30–60mg once daily.",
          "Oral Carbamazepine (unlicensed; licensed for trigeminal neuralgia): Use as addition to pregabalin. 100mg 1–2×/d (higher initial dose possible), increase gradually; usual dose 200mg 3–4×/d, up to 1.6–2.0g/d.",
          "Oral Tramadol Hydrochloride (Controlled drug rescue treatment): 50mg 3×/d then 50–100mg every 4–6h. Chronic pain: 50mg then adjust; total >400mg daily not usually required."
        ]
      },
      {
        "title": "Miscellaneous Conjunctivitis",
        "icon": "biotech",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Condition",
            "Features & Etiology",
            "Treatment/Investigations"
          ],
          "rows": [
            [
              "Toxic Conjunctivitis",
              "Reaction to meds (aminoglycosides, antivirals, glaucoma tx, preservatives, Cl solutions). Inferior papillary reaction. Chronic use: follicular reaction, cicatrization, punctate epitheliopathy.",
              "Discontinue precipitating agent; consider preservative-free lubricant (e.g. carmellose)."
            ],
            [
              "Parinaud Oculoglandular Syndrome",
              "Rare unilateral conjunctivitis; granulomatous nodules/follicles; preauricular/submandibular lymphadenopathy; systemic upset (malaise, fever). Causes: Cat-scratch (Bartonella henselae), tularaemia, TB, sarcoid, syphilis, fungi.",
              "Biopsy, swabs, FBC, VDRL, CXR, Mantoux, serology (cat-scratch/tularaemia)."
            ],
            [
              "Ligneous Conjunctivitis",
              "Rare idiopathic chronic (mostly girls); recurrent 'wood-like' membranes on tarsal conjunctiva/mucous membranes. Histology: fibrin, albumin, IgG, T & B cells.",
              "Topical ciclosporin (0.1% drops or 0.2% ointment). Note: 0.2% ointment is unlicensed veterinary preparation used off-label."
            ]
          ]
        }
      },
      {
        "title": "Conjunctival Degenerations",
        "icon": "visibility",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Condition",
            "Clinical Features",
            "Treatment"
          ],
          "rows": [
            [
              "Pinguecula",
              "Yellow-white patch of interpalpebral bulbar conjunctiva (nasal/temporal). Elastotic degeneration of collagen.",
              "Reassurance; occasional ocular lubrication."
            ],
            [
              "Pterygium",
              "Triangular fibrovascular band; nasal limbus; associated with UV/dry climates. Destroys Bowman's layer. Stable sign: Stocker line. Active signs: engorgement, inflammation, grey leading edge.",
              "Excision with conjunctival autograft. AMG or MMC for recurrence. Lamellar keratoplasty if visual axis involved."
            ],
            [
              "Concretions",
              "Yellow-white deposits; common in elderly/chronic blepharitis. FB sensation if eroded.",
              "Remove with needle at slit-lamp under topical anaesthetic."
            ],
            [
              "Retention Cyst",
              "Thin-walled, fluid-filled. May disturb tear film.",
              "Puncture with needle or excision if recurrent."
            ]
          ]
        }
      },
      {
        "title": "Pigmented Lesions: Benign",
        "icon": "palette",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Congenital Epithelial Melanosis: Racial, bilateral, flat, patchy brown. Often denser around limbus/anterior ciliary nerves or Axenfeld loop.",
          "Conjunctival Freckle: Common, tiny, flat, freely moving.",
          "Melanocytoma: Rare, black, fixed, slowly growing.",
          "Acquired Deposits: Mascara (inferior fornix), coal dust tattoos, adrenochrome (from chronic adrenaline)."
        ]
      },
      {
        "title": "Pigmented Lesions: Premalignant",
        "icon": "priority_high",
        "type": "table",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "headers": [
            "Type",
            "Details"
          ],
          "rows": [
            [
              "Primary Acquired Melanosis (PAM)",
              "Uncommon; rare in African-Caribbeans. Without atypia = benign. With atypia = 50% risk of melanoma by 5y. Unilateral, irregular brown pigmentation. Nodules suggest malignant transformation."
            ],
            [
              "Conjunctival Naevus",
              "Uncommon; low risk. Defined brown pigmentation ± cysts (limbus/caruncle). Extension to cornea suggests malignancy."
            ],
            [
              "PAM Treatment",
              "For atypia: Excision + cryotherapy/radiotherapy/antimetabolite."
            ]
          ]
        }
      },
      {
        "title": "Congenital Ocular Melanocytosis",
        "icon": "face",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "blue",
        "content": "Uncommon. Oculodermal melanocytosis (naevus of Ota) is the most common variant (more in orientals/men). Features: subconjunctival flat grey lesions; unilateral facial hyperpigmentation (Va/b distribution); ipsilateral iris hyperchromia, iris mamillations, glaucoma (10%), and risk of melanoma (ocular, dermal, or CNS)."
      },
      {
        "title": "Malignant Melanoma",
        "icon": "dangerous",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Consider first for abnormal pigmentation; may be fatal.",
          "Common in middle age; arises from PAM, naevus, or de novo.",
          "Signs: Grey/black/non-pigmented vascularized nodule fixed to episclera; usually at limbus.",
          "Metastasis: Lymph nodes, lung, liver, brain.",
          "Five-year mortality: 13%.",
          "Poor prognosis: Thickness >1mm, recurrence, multifocal, caruncle/fornix/palpebral location, spread."
        ]
      },
      {
        "title": "Melanoma Treatment",
        "icon": "settings_suggest",
        "type": "process",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Step 1: Wide local excision",
          "Step 2: Double freeze-thaw cryotherapy to margins",
          "Step 3: Adjunctive radiotherapy/antimetabolite if incomplete",
          "Step 4: Exenteration if unresectable"
        ]
      },
      {
        "title": "Benign Non-Pigmented Lesions (1)",
        "icon": "bubble_chart",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "Papilloma (Pedunculated): Teenage+; HPV 6, 11, 16, 18. Palpebral/forniceal/caruncular. Association with HIV. Tx: Surgery, cryo, cimetidine, MMC, IFN. Send for HPV PCR.",
          "Papilloma (Sessile): Middle age; bulbar/limbal. Unilateral. Tx: Excision. Send for HPV PCR.",
          "Epibulbar Choristoma (Dermoids): Childhood; Goldenhar syndrome. Soft yellow limbal mass. Tx: Lamellar graft.",
          "Lipodermoid: Adults. Soft white mass at lateral canthus. Tx: CT scan required for forniceal lesions to rule out intraorbital/intracranial extension.",
          "Ectopic Lashes: Subconjunctival cilia.",
          "Pyogenic Granuloma: Rapidly growing red vascular mass after trauma/surgery."
        ]
      },
      {
        "title": "Premalignant & Malignant Non-Pigmented Lesions (2)",
        "icon": "warning",
        "type": "table",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": {
          "headers": [
            "Condition",
            "Clinical Features",
            "Treatment"
          ],
          "rows": [
            [
              "Conjunctival Intraepithelial Neoplasia (CIN)",
              "Rare; age >50. Dysplasia/Carcinoma in situ. Fleshy, moving mass with tufted vessels at limbus. May transform to SCC.",
              "Excision + MMC ± cryotherapy. 3 cycles (1wk on/off) MMC/5-Fu drops. Plug lower punctum."
            ],
            [
              "Ocular Surface Squamous Neoplasia (OSSN)",
              "Most common malignant conjunctival tumor worldwide. Risk: UV, HPV, HIV. Gelatinous mass, infiltrates cornea/sclera/globe.",
              "Excision (2-3mm margins) + MMC/cryo. Topical IFN-α-2a or subconjunctival IFN for resistant cases. Enucleation for advanced disease."
            ],
            [
              "Conjunctival Kaposi’s Sarcoma",
              "Bright red mass (inferior fornix); mimics hemorrhage. Caused by HHV8 (check HIV).",
              "Biopsy (HHV8 PCR); focal radiotherapy if aggressive."
            ]
          ]
        }
      },
      {
        "title": "Conjunctival Lymphoma & Rare Tumors",
        "icon": "biotech",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "Conjunctival Lymphoma: Salmon-pink infiltrate (fornices). Usually B-cell non-Hodgkin’s. histology essential. Referral for imaging/oncology. Tx: Excision, cryo, subconjunctival IFN-α-2b, or radiotherapy. EBV PCR.",
          "Muco-epidermoid Carcinoma: Very rare, aggressive; mimics pterygium. Arises from mucus-secreting and squamous cells.",
          "Infiltration from lid tumors: Sebaceous cell carcinoma of lid spreading to conjunctiva; presents as unilateral cicatrizing conjunctivitis."
        ]
      },
      {
        "title": "Key Points for Clinical Practice",
        "icon": "stars",
        "type": "remember",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "BENIGN vs MALIGNANT",
          "explanation": "Stable, regular, flat, asymptomatic = likely Benign. Growing, irregular, elevated, symptomatic (bleeding, itchy, painful) = likely Malignant. SEEK SPECIALIST ADVICE FOR ALL POTENTIALLY MALIGNANT LESIONS."
        }
      },
      {
        "title": "References & Literature",
        "icon": "menu_book",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "18. Rosenthal P et al. Corneal pain without stain: is it real? Ocul Surf. 2009;7:28–40. | 19. NICE CG173: Neuropathic pain in adults: pharmacological management. 2013 (updated 2017). | 20. Dieckmann G et al. Neuropathic Corneal Pain: Approaches for Management. Ophthalmology 2017. | 21. Karcioglu ZA et al. HPV in neoplastic/non-neoplastic conditions. Br J Ophthalmol. 1997. | 22. Tulvatana W et al. Risk factors for OSSN. Br J Ophthalmol. 2003. | 23. Ross JJ et al. Systemic remission of NHL after intralesional IFN α-2b. Am J Ophthalmol. 2004."
      }
    ],
    "chapterId": "neuro"
  },
  "chapterId": "neuro",
  "_newlyImported": 1769622344984,
  "communityId": "sub_1769618268159_j85dphq224a2m6",
  "communityAuthor": "Dodiii",
  "communityDate": "2026-01-28T16:37:48.159Z"
}